Commercialising the Next Generation of Synthetic Lethality: preclinical validation of lead drug-targets and discovery platform
下一代合成致死剂的商业化:主要药物靶点和发现平台的临床前验证
基本信息
- 批准号:10015870
- 负责人:
- 金额:$ 44.6万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Collaborative R&D
- 财政年份:2022
- 资助国家:英国
- 起止时间:2022 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
**Background:**Gliomas are the commonest type of brain-cancer worldwide. They affect adults as well as children and cause **227,000 deaths** globally every year. Patients suffer with seizures, headaches, vomiting, blindness and personality-changes before **death follows in 95%** of high-grade cases. In addition to the terrible human cost, the burden of gliomas on the UK economy is over **£1billion/year** in NHS costs, social-care and sick-leave expenses.Today, glioma treatment involves surgery followed by radiotherapy and chemotherapy. However, despite aggressive treatment, gliomas are still almost universally fatal and no new drugs have been developed in over 15 years. A major problem is that glioma tumours tend to evolve resistance to drugs and so relapses are common.**Innovation:****CoSyne Therapeutics** is a precision-medicine company based in London. Our goal is to revolutionise the way we treat brain-cancers. We are a spin-out from Imperial College London and are building on many years of academic research in the field.The heart of our innovation is our state-of-the-art computational platform, which utilises machine-learning to find new ways to treat cancer. Our platform is able to identify genetic features in brain tumours that make them vulnerable to drugs that inhibit genes. We can then use this information to develop new drugs tailored to each individual patient's specific brain tumour.Our technology has the potential to overcome the problem of drug-resistance in gliomas and could lead to a new class of precision-drugs against brain tumours. Our technology can also be scaled to other cancers beyond gliomas, and so has the potential to generate many new drugs in the fight against cancer.**Project:**With this Innovate UK grant, we will validate our computational platform and our most promising drug-targets by showing that our technology can successfully treat brain-cancers in mice. This would be a game-changing milestone for our company and would attract considerable investment to allow us to create new drugs and progress them to clinical trials.**Our vision:**Today, patients receive non-targeted chemotherapy after they have their tumours surgically removed. We envisage a future whereby patients have their tumours genetically-sequenced after surgery to identify the exact genes present in each tumour. Precision drugs would then be selected based on the specific genetic-makeup of that tumour. Each patient would thus receive a drug tailored to the exact molecular/genetic features of their cancer. This project will therefore bring us significantly closer to realising this goal of curing cancers with precision-drugs.
**背景:**胶质瘤是世界上最常见的脑癌类型。它们影响成人和儿童,每年在全球造成227,000人死亡。95%的高级别病例在死亡前会出现癫痫、头痛、呕吐、失明和性格改变等症状。除了可怕的人力成本,神经胶质瘤给英国经济带来的负担每年超过10亿英镑,其中包括国民医疗服务体系(NHS)的成本、社会保健和病假费用。如今,神经胶质瘤的治疗包括手术后的放疗和化疗。然而,尽管进行了积极的治疗,胶质瘤仍然几乎是普遍致命的,并且在过去的15年里没有开发出新的药物。一个主要的问题是,神经胶质瘤倾向于进化出对药物的耐药性,因此复发是常见的。**创新:****CoSyne Therapeutics**是一家总部位于伦敦的精准医疗公司。我们的目标是彻底改变我们治疗脑癌的方式。我们是从伦敦帝国理工学院分拆出来的,建立在该领域多年的学术研究基础上。我们创新的核心是我们最先进的计算平台,它利用机器学习来寻找治疗癌症的新方法。我们的平台能够识别脑肿瘤的遗传特征,这些特征使它们容易受到抑制基因药物的影响。然后,我们可以利用这些信息开发针对每个患者特定脑肿瘤的新药。我们的技术有可能克服神经胶质瘤的耐药性问题,并可能导致一种针对脑肿瘤的新型精确药物。我们的技术也可以扩展到神经胶质瘤以外的其他癌症,因此有可能产生许多对抗癌症的新药。**项目:**有了Innovate UK的资助,我们将通过展示我们的技术可以成功治疗小鼠脑癌来验证我们的计算平台和我们最有希望的药物靶点。对于我们公司来说,这将是一个改变游戏规则的里程碑,并将吸引大量投资,使我们能够开发新药并将其推进临床试验。**我们的愿景:**今天,患者在手术切除肿瘤后接受非靶向化疗。我们设想未来病人在手术后对他们的肿瘤进行基因测序,以确定每个肿瘤中存在的确切基因。然后根据肿瘤的特定基因组成选择精准药物。因此,每位患者都将接受针对其癌症分子/基因特征量身定制的药物。因此,这个项目将使我们更接近实现用精准药物治疗癌症的目标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
其他文献
吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('', 18)}}的其他基金
An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
- 批准号:
2901954 - 财政年份:2028
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
- 批准号:
2896097 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
- 批准号:
2780268 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
- 批准号:
2908918 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
- 批准号:
2908693 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
- 批准号:
2908917 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
- 批准号:
2879438 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
- 批准号:
2890513 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
- 批准号:
2879865 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
- 批准号:
2876993 - 财政年份:2027
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
相似国自然基金
Next Generation Majorana Nanowire Hybrids
- 批准号:
- 批准年份:2020
- 资助金额:20 万元
- 项目类别:
相似海外基金
Next Generation Glioma Treatments using Direct Light Therapy
使用直接光疗法的下一代神经胶质瘤治疗
- 批准号:
10092859 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
EU-Funded
Next-generation KYC banking verification via embedded smart keyboard
通过嵌入式智能键盘进行下一代 KYC 银行验证
- 批准号:
10100109 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Collaborative R&D
Safe and Sustainable by Design framework for the next generation of Chemicals and Materials
下一代化学品和材料的安全和可持续设计框架
- 批准号:
10110559 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
EU-Funded
Next-Generation Distributed Graph Engine for Big Graphs
适用于大图的下一代分布式图引擎
- 批准号:
DP240101322 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Discovery Projects
Next Generation Fluorescent Tools for Measuring Autophagy Dynamics in Cells
用于测量细胞自噬动态的下一代荧光工具
- 批准号:
DP240100465 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Discovery Projects
PhD in the Next Generation of Organic LEDs
下一代有机 LED 博士
- 批准号:
2904651 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Studentship
van der Waals Heterostructures for Next-generation Hot Carrier Photovoltaics
用于下一代热载流子光伏的范德华异质结构
- 批准号:
EP/Y028287/1 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Fellowship
MagTEM2 - the next generation microscope for imaging functional materials
MagTEM2 - 用于功能材料成像的下一代显微镜
- 批准号:
EP/Z531078/1 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Research Grant
FLF Next generation atomistic modelling for medicinal chemistry and biology
FLF 下一代药物化学和生物学原子建模
- 批准号:
MR/Y019601/1 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Fellowship
Collaborative Research: Constraining next generation Cascadia earthquake and tsunami hazard scenarios through integration of high-resolution field data and geophysical models
合作研究:通过集成高分辨率现场数据和地球物理模型来限制下一代卡斯卡迪亚地震和海啸灾害情景
- 批准号:
2325311 - 财政年份:2024
- 资助金额:
$ 44.6万 - 项目类别:
Standard Grant